Sterling Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Sterling Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2K	Sell	3,546 -2,301	-39%	-$6.44K	﹤0.01%	2162
2026 Q1	$16K	Sell	5,847 -3,513	-38%	-$11.1K	﹤0.01%	2124
2025 Q4	$34.6K	Buy	9,360 +81	+0.9%	+$262	﹤0.01%	1944
2025 Q3	$24.6K	Buy	9,279 +5,273	+132%	+$10.2K	﹤0.01%	2045
2025 Q2	$3.94K	Buy	4,006 +1,579	+65%	+$1.58K	﹤0.01%	2636
2025 Q1	$3.5K	Sell	2,427 -2,031	-46%	-$3.74K	﹤0.01%	2333
2024 Q4	$9.81K	Buy	4,458 +3,968	+810%	+$9.26K	﹤0.01%	2171
2024 Q3	$809	Buy	+490	New	+$989	﹤0.01%	2648

Other funds holding ESPR

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

OBAM

ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Sterling Capital Management's ESPR Position: Q2 2026 in Review

Sterling Capital Management reduced its Esperion Therapeutics (ESPR) stake by 39% in Q2 2026, selling an estimated $6.44K and leaving 3,546 shares worth $11.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2162.

Sterling Capital Management first reported a position in ESPR in Q3 2024 and has held it in 8 quarters since. The position peaked at $34.6K in Q4 2025. 192 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

Sterling Capital Management held 3,546 shares of Esperion Therapeutics worth $11.2K as of Q2 2026.
Sterling Capital Management sold 2,301 Esperion Therapeutics shares in Q2 2026, an estimated $6.44K.
Esperion Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2162 holding.
Sterling Capital Management first reported a position in Esperion Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Esperion Therapeutics position peaked at $34.6K in Q4 2025.
192 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.